Rosier, M.; Krstulović, A.; Kim, H.R.; Kaur, N.; Enakireru, E.M.; Symmes, D.; Dobra, K.; Chen, R.; Evans, C.A.; Gad, A.K.B.
The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. Cancers 2025, 17, 81.
https://doi.org/10.3390/cancers17010081
AMA Style
Rosier M, Krstulović A, Kim HR, Kaur N, Enakireru EM, Symmes D, Dobra K, Chen R, Evans CA, Gad AKB.
The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. Cancers. 2025; 17(1):81.
https://doi.org/10.3390/cancers17010081
Chicago/Turabian Style
Rosier, Marieke, Anja Krstulović, Hyejeong Rosemary Kim, Nihardeep Kaur, Erhumuoghene Mary Enakireru, Deebie Symmes, Katalin Dobra, Ruihuan Chen, Caroline A. Evans, and Annica K. B. Gad.
2025. "The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells" Cancers 17, no. 1: 81.
https://doi.org/10.3390/cancers17010081
APA Style
Rosier, M., Krstulović, A., Kim, H. R., Kaur, N., Enakireru, E. M., Symmes, D., Dobra, K., Chen, R., Evans, C. A., & Gad, A. K. B.
(2025). The Vimentin-Targeting Drug ALD-R491 Partially Reverts the Epithelial-to-Mesenchymal Transition and Vimentin Interactome of Lung Cancer Cells. Cancers, 17(1), 81.
https://doi.org/10.3390/cancers17010081
